UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 569

Sortiert nach

La motivación básica de Husserl y el sentido de la fenomenología

Anuario filosófico, 2020-12, Vol.53 (3), p.447-470

San Martín, Javier

2020

Volltextzugriff (PDF)

Long‐lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5‐selective GABAA inverse agonist

British journal of pharmacology, 2020-03, Vol.177 (5), p.1106-1118

2020

Volltextzugriff (PDF)

Axonal GABAA receptors depolarize presynaptic terminals and facilitate transmitter release in cerebellar Purkinje cells

The Journal of physiology, 2017-12, Vol.595 (24), p.7477-7493

2017

Volltextzugriff (PDF)

The tactics of modern-day regulatory trials

Journal of bone and joint surgery. American volume, 2012-07, Vol.94 Suppl 1, p.39

2012

Volltextzugriff (PDF)

Las condiciones de posibilidad de la ética. Reseña de: Edmund Husserl, Introducción a la ética, trad. de M. Chu, M. Crespo y L. R. Rabanaque, Madrid, Editorial Trotta, 2020

Isegoría : revista de filosofía moral y política, 2022-07 (66), p.r06

San Martín, Javier

2022

Volltextzugriff (PDF)

FRI-161 Correlation of non-invasive tests with histological features and intrahepatic Z-alpha-1 antitrypsin burden in patients with alpha-1 antitrypsin deficiency-associated liver disease

Journal of hepatology, 2024-06, Vol.80, p.S696-S697

2024

Volltextzugriff (PDF)

FRI-164 Proteomic analysis identified fazirsiran treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver disease

Journal of hepatology, 2024-06, Vol.80, p.S698-S698

2024

Volltextzugriff (PDF)

Plozasiran (ARO-APOC3), an investigational RNAI therapeutic, demonstrates profound and durable reductions in APOC-3 and triglycerides (TG) in patients with severe hypertriglyceridemia (SHTG), SHASTA-2 final results

Atherosclerosis, 2024-08, Vol.395

2024

Volltextzugriff (PDF)

Plozasiran (ARO-APOC3), decreases APOC3 and triglycerides (TG) in patients with mixed dyslipidemia: MUIR final results

Atherosclerosis, 2024-08, Vol.395

2024

Volltextzugriff (PDF)

Modelos Rasch: ¿cuán (in-)coherentemente son presentados y utilizados?

Actualidades en psicología, 2015-12, Vol.29 (119), p.91-102

San Martin Gutiérrez, Ernesto Javier

2015

Volltextzugriff (PDF)

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

Nature medicine, 2023-09, Vol.29 (9), p.2216-2223

2023

Volltextzugriff (PDF)

El Quijote como un tratado sobre la realidad, desde Meditaciones del Quijote

Revista de filosofía (México), 2021-01, Vol.49 (143), p.67-85

San Martín Sala, Javier

2021

Volltextzugriff (PDF)

La crítica de Antonio Rodríguez Huéscar al idealismo de Husserl

Bajo palabra (Madrid, Spain), 2015-12 (11), p.51-62

San Martín, Javier

2015

Volltextzugriff (PDF)

Methode und Subjektivität: Eine Betrachtung über die Erneuerung der phänomenologischen Wissenschaft der Subjektivität

Journal für Psychologie, 2023-07, Vol.31 (1), p.125-150

2023

Volltextzugriff (PDF)

Fazirsiran for Liver Disease Associated with Alpha 1 -Antitrypsin Deficiency

The New England journal of medicine, 2022-08, Vol.387 (6), p.514-524

2022

Volltextzugriff (PDF)

Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results

Journal of clinical lipidology, 2024-07, Vol.18 (4), p.e560-e560

2024

Volltextzugriff (PDF)

Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results

Journal of clinical lipidology, 2024-07, Vol.18 (4), p.e564-e564

2024

Volltextzugriff (PDF)

Reduction of intra-hepatic Z-AAT synthesis by fazirsiran decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency

Journal of hepatology, 2022-07, Vol.77, p.S14

2022

Volltextzugriff (PDF)

Impact of single-site axonal GABAergic synaptic events on cerebellar interneuron activity

The Journal of cell biology, 2015-12, Vol.211 (6), p.2116

2015

Volltextzugriff (PDF)

Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)

Gastroenterology (New York, N.Y. 1943), 2024-07

2024

Volltextzugriff (PDF)

What may GLP1 receptor agonists contribute to the treatment of patients with non-alcoholic fatty liver disease?

Revista española de enfermedades digestivas, 2020-08, Vol.112 (8), p.587

Escalada San Martin, Francisco Javier

2020

Volltextzugriff (PDF)

Abstract 10357: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia

Circulation (New York, N.Y.), 2021-11, Vol.144 (Suppl_1)

2021

Volltextzugriff (PDF)

1 – 25 von 569

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(312)
Mit Volltextzugriff
(466)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Investigaciones Fenomenológicas
(80)
Blood
(44)
Arte Y Parte
(28)
Lapiz
(20)
Archivos Españoles De Urología
(18)
Endocrinología, Diabetes Y Nutrición
(14)
Horizonte Médico
(14)
Revista Española De Cardiologia
(12)
Nefrología
(10)
Endocrinología, Diabetes Y Nutrición.
(9)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

La motivación básica de Husserl y el sentido de la fenomenología

Long‐lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5‐selective GABAA inverse agonist

Axonal GABAA receptors depolarize presynaptic terminals and facilitate transmitter release in cerebellar Purkinje cells

Information and consensus document for the detection and management of chronic kidney disease

The tactics of modern-day regulatory trials

Las condiciones de posibilidad de la ética. Reseña de: Edmund Husserl, Introducción a la ética, trad. de M. Chu, M. Crespo y L. R. Rabanaque, Madrid, Editorial Trotta, 2020

FRI-161 Correlation of non-invasive tests with histological features and intrahepatic Z-alpha-1 antitrypsin burden in patients with alpha-1 antitrypsin deficiency-associated liver disease

FRI-164 Proteomic analysis identified fazirsiran treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver disease

Plozasiran (ARO-APOC3), an investigational RNAI therapeutic, demonstrates profound and durable reductions in APOC-3 and triglycerides (TG) in patients with severe hypertriglyceridemia (SHTG), SHASTA-2 final results

Plozasiran (ARO-APOC3), decreases APOC3 and triglycerides (TG) in patients with mixed dyslipidemia: MUIR final results

Modelos Rasch: ¿cuán (in-)coherentemente son presentados y utilizados?

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

El Quijote como un tratado sobre la realidad, desde Meditaciones del Quijote

La crítica de Antonio Rodríguez Huéscar al idealismo de Husserl

Methode und Subjektivität: Eine Betrachtung über die Erneuerung der phänomenologischen Wissenschaft der Subjektivität

Fazirsiran for Liver Disease Associated with Alpha 1 -Antitrypsin Deficiency

Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Robust and Durable TG Reductions in Patients with Mixed Dyslipidemia, MUIR Final Results

Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results

Reduction of intra-hepatic Z-AAT synthesis by fazirsiran decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency

Impact of single-site axonal GABAergic synaptic events on cerebellar interneuron activity

Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)

Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study

OS-120 - Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study

What may GLP1 receptor agonists contribute to the treatment of patients with non-alcoholic fatty liver disease?

Abstract 10357: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia

Aktive Filter

Suchergebnisse filtern